OBJECTIVES: Given the roles of bcl-2, bax and p53 in apoptosis, we investigated the effect of their expression on the response to cisplatin in order to understand the molecular events of cisplatin-resistance in lung cancers. METHODS: Three parental human lung cancer cell lines (PC9, PC14 and H69) and their in vitro selected cisplatin-resistant sublines were examined. Cells treated with cisplatin were processed for acridine orange and ethidium bromide staining and DNA gel electrophoresis for the morphologic detection of apoptosis. The endogenous levels of bcl-2, bax and p53 protein expression in lung cancer cells were assessed by Western blot analysis and DNA of polymerase chain reaction-amplified exon 5 to 8 of p53 gene was directly sequenced. RESULTS: H69, which had bcl-2 expression, p53 mutation and decreased expression of p53 and bax, was relatively resistant to cisplatin and delayed and reduced apoptosis. Although apoptosis was markedly reduced in cisplatin-resistant sublines compared to their parental cells, there were no significant differences in the expression of p53, bcl-2 and bax. CONCLUSIONS: Cisplatin-resistance was associated with the reduced cellular susceptibility to apoptosis. Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis.
OBJECTIVES: Given the roles of bcl-2, bax and p53 in apoptosis, we investigated the effect of their expression on the response to cisplatin in order to understand the molecular events of cisplatin-resistance in lung cancers. METHODS: Three parental human lung cancer cell lines (PC9, PC14 and H69) and their in vitro selected cisplatin-resistant sublines were examined. Cells treated with cisplatin were processed for acridine orange and ethidium bromide staining and DNA gel electrophoresis for the morphologic detection of apoptosis. The endogenous levels of bcl-2, bax and p53 protein expression in lung cancer cells were assessed by Western blot analysis and DNA of polymerase chain reaction-amplified exon 5 to 8 of p53 gene was directly sequenced. RESULTS: H69, which had bcl-2 expression, p53 mutation and decreased expression of p53 and bax, was relatively resistant to cisplatin and delayed and reduced apoptosis. Although apoptosis was markedly reduced in cisplatin-resistant sublines compared to their parental cells, there were no significant differences in the expression of p53, bcl-2 and bax. CONCLUSIONS:Cisplatin-resistance was associated with the reduced cellular susceptibility to apoptosis. Cancer cells with the natural expression of bcl-2 and p53 mutation may be more resistant to cisplatin and less susceptible to apoptosis.
Authors: A R Gottschalk; L H Boise; Z N Oltvai; M A Accavitti; S J Korsmeyer; J Quintáns; C B Thompson Journal: Cell Death Differ Date: 1996-01 Impact factor: 15.828
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: Natalia Estrada-Ortiz; Elena Lopez-Gonzales; Ben Woods; Stefan Stürup; Inge A M de Graaf; Geny M M Groothuis; Angela Casini Journal: Toxicol Res (Camb) Date: 2019-09-20 Impact factor: 3.524
Authors: Ji-Youn Han; Eun Kyung Hong; Byung Gil Choi; Jin No Park; Ki Won Kim; Jin Hyung Kang; Jong-Youl Jin; Suk Young Park; Young Seon Hong; Kyung Shik Lee Journal: Med Oncol Date: 2003 Impact factor: 3.064
Authors: Fernando Mendes; Tiago Sales; Cátia Domingues; Susann Schugk; Ana Margarida Abrantes; Ana Cristina Gonçalves; Ricardo Teixo; Rita Silva; João Casalta-Lopes; Clara Rocha; Mafalda Laranjo; Paulo César Simões; Ana Bela Sarmento Ribeiro; Maria Filomena Botelho; Manuel Santos Rosa Journal: Med Oncol Date: 2015-11-18 Impact factor: 3.064
Authors: Sarah Carden; Pauline van der Watt; Alicia Chi; Aderonke Ajayi-Smith; Katie Hadley; Virna D Leaner Journal: BMC Cancer Date: 2018-11-16 Impact factor: 4.430